Comparing Sun Pharma, Dr. Reddy’s, and Cipla’s Q1 FY26 Performance

Introduction

India’s economic growth has been closely linked to the strength of its core industries, and pharmaceuticals stand out as a vital contributor. Often called the “Pharmacy of the World,” India has built a reputation as a reliable supplier of affordable and high-quality medicines across global markets. The sector not only drives exports and foreign investment but also sustains millions of livelihoods at home. In recent years, companies such as Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla have emerged as leading players shaping both domestic and international growth stories. Their quarterly results provide an important lens to understand how Indian pharma giants are balancing expansion, innovation, and profitability in a rapidly evolving healthcare landscape.

Industry Overview

India today holds the third position worldwide in pharmaceutical production by volume and ranks fourteenth by value, reflecting its competitive advantage in generics and cost-efficient manufacturing. The sector is powered by a network of more than 10,500 manufacturing units and around 3,000 pharmaceutical companies, many of which are certified by global regulators such as the USFDA. This robust infrastructure has enabled India to meet nearly 20% of global demand for generic medicines, with drug and pharma exports touching USD 27 billion in FY24 and contributing to a trade surplus of nearly USD 19 billion.

Looking ahead, the Indian pharmaceutical industry is expected to expand significantly, driven by rising domestic consumption, growing demand in emerging markets, and an increasing focus on specialty and complex generics. Estimates suggest the market could reach USD 130 billion by FY30 and as high as USD 450 billion by FY47. These growth prospects underline the sector’s strategic importance, not just for India’s economy but also for global healthcare.

Company Overview: Sun Pharma, Dr. Reddy’s, and Cipla

Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries, a leading player in India’s pharmaceutical sector, displayed a mixed performance in Q1 FY26. On a standalone basis, the company’s net profit surged to Rs. 753.53 crore, more than three times the Rs. 237.82 crore reported in the same period last year, driven by robust revenue growth. Total standalone income rose 24.55% to Rs. 5,705.65 crore, highlighting strong operational performance and demand across key markets.

On a consolidated level, however, Sun Pharma’s net profit fell by nearly 20%, amounting to Rs. 2,278.63 crore compared to Rs. 2,835.62 crore in Q1 FY25, even as total consolidated revenue increased 8.57% to Rs. 14,315.86 crore. This contrast reflects challenges in certain international markets and the impact of competitive pressures, even as the company’s diversified portfolio, global reach, and sustained focus on research and development continue to underpin its market leadership.

Dr Reddy's Laboratories Ltd

Dr. Reddy’s Laboratories, a prominent player in the Indian pharmaceutical industry with a significant international presence, reported solid growth in Q1 FY26. On a standalone basis, the company’s net profit rose sharply to Rs. 2,961.20 crore, more than double the Rs. 1,417.20 crore recorded in the same period last year, fueled by a 35.46% increase in total income, which reached Rs. 8,207.80 crore. This demonstrates strong demand across its key segments and markets.

On a consolidated level, the company posted a modest 1.85% rise in net profit, amounting to Rs. 1,418.10 crore compared to Rs. 1,392.40 crore in Q1 FY25. Total consolidated revenue grew 12.41% to Rs. 8,862.40 crore, reflecting steady performance in both domestic and international markets. The results highlight Dr. Reddy’s continued focus on innovation, operational efficiency, and a diversified portfolio, reinforcing its position as one of India’s leading pharmaceutical companies.

Cipla Ltd

Cipla, a leading Indian pharmaceutical company recognized for its expertise in respiratory, oncology, and chronic care therapies, posted steady growth in Q1 FY26. On a standalone basis, the company’s net profit rose 23.41% to Rs. 1,303.13 crore, compared to Rs. 1,055.94 crore in the same quarter last year, supported by a 12.78% increase in total income, which reached Rs. 5,317.24 crore. This performance highlights strong demand across its core product lines and key markets.

On a consolidated basis, Cipla’s net profit increased 10.19% to Rs. 1,297.62 crore, up from Rs. 1,177.64 crore in Q1 FY25, while total consolidated revenue grew 5.28% to Rs. 7,216.03 crore. These results underscore the company’s ability to sustain growth across domestic and international operations, driven by a diversified product portfolio, consistent market demand, and continued investments in research and development. Cipla’s performance in Q1 FY26 reinforces its position as one of India’s foremost pharmaceutical firms.

Quarterly Earnings Analysis: Sun Pharma vs. Dr. Reddy’s vs. Cipla (Q1 FY26)

The table below presents a side-by-side comparison of Q1 FY26 financial performance for Sun Pharma, Dr. Reddy’s, and Cipla. It highlights key metrics such as net profit, revenue, and growth trends to provide a clear view of each company’s performance.

Revenue Performance

Sun Pharma maintained its leadership with a total revenue of Rs. 13,851.40 crore, nearly 1.6 times Dr. Reddy’s Rs. 8,572.10 crore and almost double Cipla’s Rs. 6,957.47 crore. The gap highlights Sun’s broad global presence and diversified therapeutic portfolio. Dr. Reddy’s continues to hold a strong second position, while Cipla, though smaller in scale, is showing resilience with consistent revenue growth.

Gross Profit & Cost of Revenue

Sun Pharma also led in gross profit at Rs. 10,971.31 crore, demonstrating its strong pricing power and efficiency. Dr. Reddy’s and Cipla reported Rs. 4,862.70 crore and Rs. 4,786.76 crore, respectively, which are almost identical despite Cipla having lower revenue. This reflects Cipla’s lean cost structure, supported by its cost of revenue of Rs. 2,170.71 crore, which is much lower than Dr. Reddy’s Rs. 3,682.50 crore. Sun, operating at scale, had the highest cost of revenue at Rs. 2,814.76 crore, but its margins remain strong.

Operating Expenses

Sun Pharma’s total operating expenses stood at Rs. 9,778.78 crore, higher due to its size and global operations. Dr. Reddy’s incurred Rs. 6,398.50 crore, while Cipla managed well at Rs. 5,179.33 crore. Looking deeper, Sun had the highest Selling, General & Administrative (SG&A) expenses at Rs. 2,801.66 crore, followed by Dr. Reddy’s Rs. 2,318.10 crore, while Cipla kept this in check at Rs. 1,312.30 crore.

In Research & Development (R&D), Sun spent Rs. 884.10 crore, reaffirming its commitment to specialty and complex generics. Dr. Reddy’s followed with Rs. 624.40 crore, while Cipla spent a more conservative Rs. 432 crore. Other operating expenses were significant for all three, with Cipla and Dr. Reddy’s nearly equal at Rs. 3,435.03 crore and Rs. 3,456 crore, compared to Sun’s Rs. 6,093.02 crore.

Depreciation, EBITDA & EBIT

Depreciation and amortization were in line with scale, with Sun recording Rs. 700.55 crore, Dr. Reddy’s Rs. 476.10 crore, and Cipla Rs. 252.72 crore. At the EBITDA level, Sun reported Rs. 3,924.13 crore, substantially higher than Dr. Reddy’s Rs. 2,472.30 crore and Cipla’s Rs. 2,042.27 crore. Similarly, Sun’s EBIT at Rs. 3,223.58 crore was well ahead of Dr. Reddy’s Rs. 1,995.80 crore and Cipla’s Rs. 1,789.55 crore. This confirms Sun’s superior operating leverage and efficiency.

Operating & Net Income

Sun Pharma’s operating income reached Rs. 4,072.62 crore, almost twice Dr. Reddy’s Rs. 2,173.60 crore and more than double Cipla’s Rs. 1,778.14 crore. Even after adjusting for interest income and expenses, Sun maintained its lead.

At the bottom line, Sun posted a net income of Rs. 2,278.63 crore, followed by Dr. Reddy’s Rs. 1,418.10 crore and Cipla Rs. 1,297.62 crore. Interestingly, net income from continuing operations was marginally higher for Sun at Rs. 2,302.62 crore, compared with Dr. Reddy’s Rs. 1,409.70 crore and Cipla’s Rs. 1,292.05 crore.

Interest Income & Expense

Sun earned the highest interest income at Rs. 154.24 crore, reflecting strong treasury operations, while Dr. Reddy’s earned Rs. 112.80 crore. Cipla lagged at just Rs. 14.05 crore. On the expense side, Cipla had the lowest interest outflow at Rs. 14.05 crore, compared to Dr. Reddy’s Rs. 83 crore and Sun’s Rs. 74.80 crore, highlighting Cipla’s stronger debt-light structure.

Tax Provision & Extraordinary Items

Tax outgo was in line with profitability. Sun paid Rs. 870.15 crore, Dr. Reddy’s Rs. 495.10 crore, and Cipla Rs. 477.88 crore. Sun also recorded extraordinary items of Rs. 100.51 crore, unlike the other two companies, suggesting one-off adjustments.

Earnings Per Share (EPS)

While Sun delivered the highest overall profit, its EPS stood at Rs. 9.50, reflecting its broader equity base. In contrast, Dr. Reddy’s reported an impressive Rs. 16.98 EPS, slightly ahead of Cipla’s Rs. 16.06 EPS. This shows that on a per-share basis, Dr. Reddy’s and Cipla offered stronger shareholder value compared to Sun Pharma.

Conclusion

The Q1 FY26 results of Sun Pharma, Dr. Reddy’s, and Cipla highlight the varied strengths of India’s leading pharmaceutical companies. Each firm has demonstrated resilience through a mix of revenue growth, cost management, R&D focus, and operational efficiency. While their financial structures and scale differ, the quarter reflects the sector’s continued momentum in both domestic and international markets. Overall, the performance indicates a stable and competitive environment for the pharmaceutical industry as it adapts to evolving healthcare needs and global opportunities.

For deeper insights and smarter investment decisions, explore the Enrich Money trading platform – your partner in navigating market opportunities.

With Enrich Money, you can track, compare, and invest with ease, backed by expert tools designed for today’s investors.

Frequently Asked Questions

Why is R&D spending especially important for pharma companies like Sun Pharma, Dr. Reddy’s, and Cipla?

R&D drives new drug discovery and global approvals, directly influencing long-term growth and competitiveness in the pharma sector.

How do quarterly revenues of pharma companies reflect market trends?

Revenues highlight demand in domestic and international markets, as well as the impact of generic launches and exports.

What does operating income reveal about pharma companies’ efficiency?

It reflects how well companies control costs like raw materials and manufacturing while scaling revenues from core operations.

Why should investors compare EPS across Sun Pharma, Dr. Reddy’s, and Cipla?

EPS helps measure shareholder value creation, enabling investors to compare profitability across different pharma players.

How do global regulations impact the quarterly performance of Indian pharma companies?

Approvals or compliance issues in markets like the US and EU can significantly influence revenues and investor confidence.

Disclaimer:  This blog is dedicated exclusively for educational purposes. Please note that the securities and investments mentioned here are provided for informative purposes only and should not be construed as recommendations. Kindly ensure thorough research prior to making any investment decisions. Participation in the securities market carries inherent risks, and it's important to carefully review all associated documents before committing to investments. Please be aware that the attainment of investment objectives is not guaranteed. It's important to note that the past performance of securities and instruments does not reliably predict future performance.